Table 1

Characteristics of the study population

CharacteristicsTotal population (n=62)
Demographics
Age (years) (mean (SD))67.3 (12.8)
Male (n (%))53 (85.5)
Body mass index (kg/m2) (median (IQR))27.1 (26.1 to 30.9)
Daily alcohol >30 g (n (%))9 (15.8)
Excessive sugar-sweetened beverage intake (n (%))1 (1.6)
Purine-rich diet (n (%))10 (17.9)
Gout characteristics
Symptom duration (years) (median (IQR))10 (3–16)
Subcutaneous tophi (n (%))26 (41.9)
Number of flares in past 6 months (median (IQR))2 (1–3)
Urate-lowering therapy naive (n (%))41 (66.1)
Comorbidities
History of urolithiasis (n (%))12 (19.7)
Hypertension (n (%))45 (72.6)
Chronic heart failure (n (%))18 (29.0)
History of myocardial infarction (n (%))11 (17.7)
Coronary heart disease (n (%))13 (21.0)
Cardiovascular disease26 (41.9)
History of stroke (n (%))2 (3.2)
Dyslipidaemia (n (%))29 (46.8)
Diabetes mellitus (n (%))18 (29.0)
Obstructive sleep apnoea (n (%))7 (11.3)
Treatments
Diuretics (n (%))19 (30.6)
Lipid-lowering drugs (n (%))30 (48.4)
Antihypertensive drugs (n (%))44 (71.0)
Antiplatelet/anticoagulants30 (48.4)
Laboratory findings
Serum urate level (mg/dL) (median (IQR))8.4 (6.6–9.9)
Estimated glomerular filtration rate <60 mL/min/1.73 m2 (n (%))14 (24.6)
Dual-energy CT volumes of MSU crystal deposits
Feet (cm3) (median (IQR))0.5 (0.2–1.9)
Knees (cm3) (median (IQR))0.4 (0.1–1.2)
Total (cm3) (median (IQR))1 (0.4–2.7)
  • MSU, monosodium urate.